Back to search
Intraperitoneal Chemotherapy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Intraperitoneal Chemotherapy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Intraperitoneal Chemotherapy trials you may qualify forThis study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxe…
This is a Phase II treatment study analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC in gastric a…
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel minimally invasive drug delivery system for patients with peritoneal metastases (PM). It has…
Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day…
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Adrenocortical carcinoma (ACC) is a rare tumor with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mont…
Background: Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people…